Apremilast

• Description :

  Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].

• CAS Number :

  [608141-41-9]

• Product Name Alternative :

  CC-10004

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332, H361, H372

• Target :

  Apoptosis; Phosphodiesterase (PDE) ; TNF Receptor

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Apremilast.html

• Purity :

  99.91

• Solubility :

  DMSO : 44 mg/mL (ultrasonic)

• Smiles :

  CC(NC1=CC=CC(C(N2[C@@H](C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O

• Molecular Formula :

  C22H24N2O7S

• Molecular Weight :

  460.50

• Precautions :

  H302, H312, H332, H361, H372

• References & Citations :

  [1]Perez-Aso M, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015 Sep 15;17:249.|[2]Chen LG, et al. Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. J Chromatogr Sci. 2016 Sep;54 (8) :1336-40.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  PDE4; TNFRSF5/CD40